Assessment of HyperQ Signal for Detecting Ischemia During Dobutamine Stress ECG
NCT ID: NCT00310622
Last Updated: 2007-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
150 participants
INTERVENTIONAL
2006-03-31
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Three-dimensional Methods of Analysis for the Detection of Coronary Artery Disease by Dobutamine Stress Echocardiography
NCT02240745
Comparison of the HyperQ Versus Conventional Electrocardiogram (ECG) to Detect Ischemia
NCT00917800
Dobutamine Stress Echocardiography in Cardiac Resynchronization Therapy (CRT) Patients Selection
NCT00828360
Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry
NCT01325467
Characterization of Ischemia Related Changes in Esophageal Electrocardiography
NCT01390155
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Diagnostic stage will include analysis of the hyperQ signal, aiming to classify results as ischemic or non-ischemic.
The HyperQ data will be compared to DSE results which will be used as the "gold standard" for this study unless Angiography results are obtained.
An additional comparison evaluation will be performed to assess the advantage of the HyperQ results on the ST-changes results obtained from conventional ECG.In addition all recruited subjects will be followed for up to 12 months.During this period a phone call will be performed every 3 months to evaluate cardiac status, hospitalization and especially Angiography procedures.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HyperQ Signal recording
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject signed informed consent
Exclusion Criteria
* Subjects with Wolff-Parkinson-White Syndrome
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BSP Biological Signal Processing Ltd.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Rosenmann, MD
Role: PRINCIPAL_INVESTIGATOR
Shaarey Zedek Hospital, Jerusalem, Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Department, Shaarey Zedek Hospital
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
David Rosenman, MD
Role: CONTACT
Related Links
Access external resources that provide additional context or updates about the study.
Biological Signal Processing Ltd.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHZ01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.